Vnitr Lek 2015, 61(2):147-150

Insulin analogues of patients with diabetes and renal impairment

Alena Adamíková
Diabetologické centrum Interní kliniky Krajské nemocnice T. Bati, a.s., Zlín, přednosta prim. MUDr. Jiří Latta

The main cause of renal failure is diabetic nephropathy which affects 20-40 % of diabetic patients. Diabetics with altered renal function have restricted therapeutic options due to the risk of accumulation of oral antidiabetic drugs and of their metabolites at a reduced glomerular filtration rate. Good metabolic control is very important during the early phases of nephropathy for reducing the risk of progression and in the stage of renal failure reduces the risk of progression of atherosclerosis and improves life prognosis. Metabolism of insulin is changed during renal failure, clearance of insulin is prolonged, the risk of hypoglycemia increases. Short-acting insulin analogues have faster absorption and long-acting analogues have a lower risk of hypoglycemia. Thus they can positively affect glycemic control of patients with diabetes and impaired renal function.

Keywords: diabetic nephropathy; insulin analogues; renal impairment

Received: January 30, 2015; Accepted: February 27, 2015; Published: February 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adamíková A. Insulin analogues of patients with diabetes and renal impairment. Vnitr Lek. 2015;61(2):147-150.
Download citation

References

  1. Morioka T, Emoto M, Tabata T et al. Glycemic control is a predictor for survival of diabetic patients on hemodialysis. Am J Kidney Dis 2001; 24(5): 909-913. Go to original source... Go to PubMed...
  2. Oomichi T, Emoto M, Tabata T et al. Impact of glycemic control is a predator for survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29(7):1496-1500. Go to original source... Go to PubMed...
  3. Charpentier G, Riveline JP, Varroud-Vial M Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000; 26(Suppl 4): 73-85.
  4. Biesenbach G, Bodlaj G, Ebner S et al. Metabolic control and vascular diseases under oral antidiabetic drug versus insulin therapy and/or alone during the first year of hemodialysis in type 2 diabetic patients with ESRD. Int Urol Nephrol 2011; 43(4):1155-1160. Go to original source... Go to PubMed...
  5. deBoer IH et al. DCCT/EDIC Research Group. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014; 37(1): 24-30. Go to original source... Go to PubMed...
  6. Eliasson B, Eeg-Olofsson K, Cederholm J et al. Antihyperglycaemic treatment of type 2 diabetes: results from a national diabetes register. Diabetes Metab 2007; 33(4): 269-276. Go to original source... Go to PubMed...
  7. Wutte A, Plank J, Bodenlenz M et al. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2007, 115(7): 461-467. Go to original source... Go to PubMed...
  8. Levemir 100 U/ml (Flexpen). SPC. Dostupné z WWW: <http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000528/WC500036662.pdf> nebo <http://www.sukl.cz>.
  9. Niafar M, Nakhjavani M, Esteghamati A et al. Efficacy and Safety of Insulin Glargine in Type 2 Diabetic Patients with Renal Failure. J Diabetes Metab 2012; 3(4): 1-4. Go to original source...
  10. Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24): 2545-2559. Go to original source... Go to PubMed...
  11. Shurraw S, Hemmelgarn B, Lin M et al. Association between glycemic control and averse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011; 171(21): 1920-1927. Go to original source... Go to PubMed...
  12. Képénékian L, Smagala A, Meyer L et al. Continuous glucose monitoring in hemodialyzed patients with type 2 diabetes: a multicenter pilot study. Clin Nephrol 2014; 82(4):240-246. Dostupné z DOI: <http://dx.doi.org/10.5414/CN108280>. Go to original source... Go to PubMed...
  13. Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 2014; 53(9): 787-800. Go to original source... Go to PubMed...
  14. Kiss I, Arold G, Roepstorff C et al. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet 2014; 53(2): 175-183. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.